Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Nuffield Department of Clinical Neurosciences (NDCN) have begun a clinical trial to assess whether the drug sildenafil could improve blood flow to the brain.

© Robina Weermeijer, Unsplash

University of Oxford researchers have begun a clinical trial to assess whether the drug sildenafil, more commonly known by its commercial name Viagra, could improve blood flow to the brain and so have the potential to reduce damage to small blood vessels in the brain and prevent strokes.

Chronic damage to small blood vessels deep in the brain is found in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and around 40 percent of dementia.​

Dr Alastair Webb, of the Wolfson Centre for Prevention of Stroke and Dementia (NDCN), based at the John Radcliffe Hospital, is leading the study. He explained: “There is limited evidence for how this small vessel disease develops and no specific treatment.”

“We aim to test whether sildenafil has the potential to reduce small vessel damage.”

Potential explanations for how small vessel disease develops include: a greater change in blood pressure with each beat of the heart (pulsatility), which hits the brain with increased force with each beat; or a reduced ability of the blood vessels in the brain to adapt to changes in the environment, also known as their reactivity.

Read more (Nuffield Department of Clinical Neurosciences website)

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.